niacinamide has been researched along with Cancer of Cervix in 8 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our results show that overexpression of p16(INK4a) in UCIS is neither associated with HPV infection nor p16(INK4a) gene amplification but is a consequence of enhanced RAS/MAPK signalling that promotes EMT, possibly due to Sorafenib-sensitive paracrine secretion of the EMT activator uPA." | 3.79 | Overexpression of p16(INK4a) in urothelial carcinoma in situ is a marker for MAPK-mediated epithelial-mesenchymal transition but is not related to human papillomavirus infection. ( Al Ghazal, A; Arndt, A; Cronauer, MV; Kraft, K; Müller, J; Schrader, AJ; Schrader, M; Skowronek, P; Steinestel, J; Steinestel, K, 2013) |
| "Sorafenib was administered daily for 7 days before the start of standard RTCT in patients with early-stage, low-risk disease and also during RTCT in patients with high-risk disease." | 2.82 | Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study. ( Chaudary, N; Clarke, B; Fan, S; Fyles, A; Glicksman, R; Haider, M; Hill, RP; Kim, S; MacKay, H; Milosevic, MF; Oza, AM; Pintilie, M; Townsley, CA; Yeung, I, 2016) |
| "Furthermore, the level of me-NAM in cervical cancer tissues of stage I, II, III, and IV was higher than that of those without lymph node metastasis." | 1.62 | Diagnostic Value of Serum N1-Methylnicotinamide in Cervical Cancer Patients. ( Ji, M; Lin, S; Na, N, 2021) |
| " The goal of this study was to elucidate the antitumor effect of the flavonoid, fisetin, combined with the multikinase inhibitor, sorafenib, against human cervical cancer cells in vitro and in vivo." | 1.43 | Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway. ( Cheng, CW; Hsieh, YH; Lin, CL; Lin, MT; Lin, TY; Tsai, JP; Wu, CC; Yang, SF, 2016) |
| "In developing countries, where 80% of cervical cancers occur, this is not always available." | 1.40 | The effect of carbogen breathing and nicotinamide added to standard (chemo)radiation treatment of advanced cervical cancer in Indonesia. ( Bekkers, RL; Bussink, J; Gondhowiardjo, S; Kaanders, JH; Leer, JW; Sekarutami, SM; Span, PN; van Weelden, WJ, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Ji, M | 1 |
| Na, N | 1 |
| Lin, S | 1 |
| Feng, Y | 1 |
| Wang, Y | 1 |
| Jiang, C | 1 |
| Fang, Z | 1 |
| Zhang, Z | 1 |
| Lin, X | 1 |
| Sun, L | 1 |
| Jiang, W | 1 |
| Steinestel, J | 1 |
| Cronauer, MV | 1 |
| Müller, J | 1 |
| Al Ghazal, A | 1 |
| Skowronek, P | 1 |
| Arndt, A | 1 |
| Kraft, K | 1 |
| Schrader, M | 1 |
| Schrader, AJ | 1 |
| Steinestel, K | 1 |
| van Weelden, WJ | 1 |
| Sekarutami, SM | 1 |
| Bekkers, RL | 1 |
| Kaanders, JH | 1 |
| Bussink, J | 1 |
| Gondhowiardjo, S | 1 |
| Leer, JW | 1 |
| Span, PN | 1 |
| Dornetshuber-Fleiss, R | 1 |
| Heilos, D | 1 |
| Mohr, T | 1 |
| Richter, L | 1 |
| Süssmuth, RD | 1 |
| Zlesak, M | 1 |
| Novicky, A | 1 |
| Heffeter, P | 1 |
| Lemmens-Gruber, R | 1 |
| Berger, W | 1 |
| Milosevic, MF | 1 |
| Townsley, CA | 1 |
| Chaudary, N | 1 |
| Clarke, B | 1 |
| Pintilie, M | 1 |
| Fan, S | 1 |
| Glicksman, R | 1 |
| Haider, M | 1 |
| Kim, S | 1 |
| MacKay, H | 1 |
| Yeung, I | 1 |
| Hill, RP | 1 |
| Fyles, A | 1 |
| Oza, AM | 1 |
| Lin, MT | 1 |
| Lin, CL | 2 |
| Lin, TY | 1 |
| Cheng, CW | 1 |
| Yang, SF | 1 |
| Wu, CC | 1 |
| Hsieh, YH | 1 |
| Tsai, JP | 1 |
| Gibbs, DF | 1 |
1 trial available for niacinamide and Cancer of Cervix
| Article | Year |
|---|---|
Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Brachytherapy; Carcinoma, Squamous Cell; | 2016 |
7 other studies available for niacinamide and Cancer of Cervix
| Article | Year |
|---|---|
Diagnostic Value of Serum N1-Methylnicotinamide in Cervical Cancer Patients.
Topics: Antigens, Neoplasm; Biomarkers, Tumor; Female; Humans; Lymphatic Metastasis; Niacinamide; Prognosis; | 2021 |
Nicotinamide induces mitochondrial-mediated apoptosis through oxidative stress in human cervical cancer HeLa cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Female; Flow Cytometry; HeLa Cells; Humans; Me | 2017 |
Overexpression of p16(INK4a) in urothelial carcinoma in situ is a marker for MAPK-mediated epithelial-mesenchymal transition but is not related to human papillomavirus infection.
Topics: Aged; Carcinoma in Situ; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Epithelial-Mesench | 2013 |
The effect of carbogen breathing and nicotinamide added to standard (chemo)radiation treatment of advanced cervical cancer in Indonesia.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carbon Dioxide; Chemoradiotherapy; Cisplat | 2014 |
The naturally born fusariotoxin enniatin B and sorafenib exert synergistic activity against cervical cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Depsipeptides; Dose-Response Relationship, Drug; D | 2015 |
Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway.
Topics: Animals; Apoptosis; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disea | 2016 |
Effect of blood on the assay of 6-phosphogluconate dehydrogenase in vaginal fluid.
Topics: Blood; Body Fluids; Female; Humans; Methods; Niacinamide; Phosphogluconate Dehydrogenase; Spectropho | 1968 |